Takeda Pharmaceutical Co.'s Actos diabetes drug may be kept on the market with new warnings, the European Medicines Agency said after reviewing research showing the drug carried a slightly increased risk of bladder cancer. "I don't think doctors are going to continue to prescribe TZD-class drugs, and as far as my practice is concerned, I will tell my patients to stop taking Actos," said Albert Levy, an endocrinologist at Mount Sinai in New York, in an e-mail. Levy has already taken his patients off Avandia, he said. Learn more